PropertyValue
?:abstract
  • Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide semi-quantitative results. Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies. Our biolayer interferometry immunosorbent assay (BLI-ISA) utilizes single-use biosensors in an automated “dip-and-read” format, providing real-time optical measurements of antigen loading, plasma antibody binding, and antibody isotype detection. Complete semi-quantitative results are obtained in less than 20 min. BLI-ISA meets or exceeds the performance of high complexity methods such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay. Importantly, our method can be immediately implemented on existing BLI platforms for urgent COVID-19 studies, such as serosurveillance and the evaluation of vaccine candidates. In a broader sense, BLI-ISA can be developed as a novel diagnostic platform to evaluate antibodies and other biomolecules in clinical specimens.
is ?:annotates of
?:creator
?:doi
  • 10.1038/s41598-020-78895-x
?:doi
?:journal
  • Sci_Rep
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/5526ec76cd7a54ade5418f0b71da8e8b479632c7.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7730435.xml.json
?:pmcid
?:pmid
?:pmid
  • 33303951.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
?:type
?:year
  • 2020-12-10

Metadata

Anon_0  
expand all